Mineralocorticoid (synthetic corticosteroid)

Fludrocortisone 21-Acetate

JAMP Fludrocortisone

Dosage form
Tablet
Available strengths
0.1 mg
Drug class
Mineralocorticoid (synthetic corticosteroid)
Common brand
JAMP Fludrocortisone

Clinical overview. Fludrocortisone acetate is an oral synthetic mineralocorticoid used as partial replacement therapy for adrenal insufficiency (Addison's disease) and for salt-losing adrenogenital syndrome. It works by promoting the body's retention of sodium and water, and is often combined with cortisone or hydrocortisone for complete hormone replacement. Because it is a potent corticosteroid, it carries risks of high blood pressure, fluid retention, increased infection susceptibility, bone loss, and other corticosteroid-related effects, and must never be stopped abruptly.

Indication

Common therapeutic uses

  • Fludrocortisone is used as partial replacement therapy for primary and secondary adrenocortical insufficiency (Addison's disease).
  • Fludrocortisone is used to treat salt-losing adrenogenital syndrome.
  • Because of its strong sodium-retaining effect, fludrocortisone is not recommended for conditions outside these approved indications.

Pregnancy

Risk assessment and monitoring considerations

  • There are no adequate, well-controlled studies of systemic corticosteroids, including fludrocortisone, in pregnant women.
  • Use during pregnancy requires weighing the possible benefit to the mother against the potential risk to the fetus.
  • Infants born to mothers who received substantial corticosteroid doses during pregnancy should be watched closely for signs of low adrenal hormone function.
  • Any corticosteroid treatment during pregnancy should be documented in the infant's medical record.

Breastfeeding

Infant exposure considerations

  • There are no adequate, well-controlled studies of fludrocortisone in breastfeeding women.
  • Other systemic corticosteroids are known to pass into human milk in low amounts.
  • Use during breastfeeding requires weighing the possible benefit to the mother against the potential risk to the nursing infant.

Geriatrics

Dosing and tolerability considerations

  • No specific safety or efficacy data are available for patients 65 years of age and older.
  • Age-related decline in kidney and liver function, and a higher rate of hypertension or heart disease, warrant closer monitoring in older adults.

Pediatrics

Use in children and adolescents

  • Health Canada has not authorized an indication for pediatric use, as no data were available for review.
  • Growth and development should be observed carefully in infants and children who require prolonged corticosteroid therapy.
  • Chronic corticosteroid use can interfere with growth in children.

Dosage & Administration

Practical dosing and administration

  • For Addison's disease, the usual oral dose is one 0.1 mg tablet once daily, though the dose may range from one tablet three times a week to two tablets (0.2 mg) once daily depending on individual needs.
  • If treatment-related high blood pressure develops, the dose is reduced to 0.05 mg daily.
  • Fludrocortisone is often given together with cortisone or hydrocortisone to complete adrenal hormone replacement.
  • For salt-losing adrenogenital syndrome, the usual oral dose is one to two tablets (0.1 to 0.2 mg) once daily.
  • The lowest dose that controls the condition should be used, with a gradual dose reduction made whenever possible.
  • Grapefruit and grapefruit juice should be avoided during treatment, since they can raise fludrocortisone blood levels.
  • Fludrocortisone should not be stopped abruptly; the dose should be tapered gradually over weeks to months.

Overdose

Recognizing and responding to overdose

If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.

  • With chronic excessive dosing, signs include high blood pressure, fluid retention or swelling, low potassium, notable weight gain, and enlargement of the heart.
  • These effects usually subside within several days after stopping the drug; treatment can then resume at a lower dose if still needed.
  • Muscle weakness from excessive potassium loss may occur and can be treated with potassium supplements.
  • Regular monitoring of blood pressure and electrolytes reduces the risk of complications from excessive dosing.
  • For large, acute overdoses, treatment includes gastric lavage or induced vomiting along with routine supportive measures.
  • Careful monitoring of electrolytes is essential, with attention to potassium replacement and limiting dietary sodium intake.

Common side effects

Frequently reported tolerability concerns

  • Nausea may occur.
  • Trouble sleeping (insomnia) may occur.
  • Headache may occur.
  • Dizziness or a spinning sensation (vertigo) may occur.
  • Weight gain may occur.
  • Fainting (syncope) may occur.
  • Slow wound healing may occur.
  • Darkening of the skin or nails may occur.
  • Muscle cramps, spasms, or aches may occur.
  • Irregular menstrual periods may occur.
  • Abnormal hair growth may occur.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • Adrenal suppression can occur, with dizziness, nausea, vomiting, abdominal pain, weakness, fatigue, and headache.
  • Severe allergic reactions, including anaphylaxis, can occur.
  • Blood clots in the leg or arm can occur, with pain, redness, swelling, and warmth.
  • Congestive heart failure can develop or worsen, with shortness of breath, fatigue, leg swelling, and a rapid or irregular heartbeat.
  • Cushing's syndrome (excess cortisol effect) can develop, with a rounded face, rapid weight gain, easy bruising, thin skin, stretch marks, and muscle weakness.
  • Diabetes or worsening blood sugar control can occur, with frequent urination and thirst.
  • Significant fluid retention (edema) can occur.
  • Eye problems, including cataracts, glaucoma, and a retinal condition called central serous chorioretinopathy, can occur.
  • Bulging of the eyes (exophthalmos) can occur.
  • High blood pressure can develop or worsen.
  • Serious infections can be masked or worsened, since corticosteroids reduce the body's ability to fight infection.
  • Mental health problems, including depression and thoughts of self-harm, can occur.
  • Bone problems, including osteoporosis and fractures of the spine or long bones, can occur.
  • A rare but serious increase in pressure around the brain (pseudotumour cerebri) has been reported, usually after stopping treatment.
  • Life-threatening and fatal cases of pheochromocytoma crisis have been reported when systemic corticosteroids were given to patients with this adrenal tumour.
  • Seek urgent medical attention for chest pain, sudden shortness of breath, signs of a severe allergic reaction, or thoughts of self-harm.

Use with caution

Situations requiring closer assessment

  • Use with caution in patients with high blood pressure, congestive heart failure, or a tendency to form blood clots.
  • Use with caution in patients with diabetes mellitus or Cushing's syndrome.
  • Use with caution in patients with peptic ulcer disease, diverticulitis, ulcerative colitis, or recent intestinal surgery.
  • Use with caution in patients with osteoporosis or risk factors for it, since corticosteroids increase calcium loss.
  • Use with caution in patients with a seizure disorder or myasthenia gravis.
  • Use with caution in patients with liver disease, since drug clearance is reduced.
  • Use with caution in patients with kidney disease, including acute or chronic nephritis.
  • Use with caution in patients with an underactive thyroid, which enhances corticosteroid effect.
  • Use with caution in patients with a history of psychiatric illness, since mood and behavioural changes can occur or worsen.
  • Use with caution in patients with eye conditions such as herpes simplex of the eye, glaucoma, or cataracts.
  • Use with caution during periods of physical stress, such as surgery, trauma, or serious illness, when a temporarily higher dose may be needed.
  • Avoid driving or operating machinery if dizziness, vision changes, or fatigue occur.
  • This product contains lactose and is not recommended for patients with rare hereditary galactose intolerance or lactase deficiency.

Contraindications

Situations where therapy may be inappropriate

  • Contraindicated in patients with known hypersensitivity to fludrocortisone or to any ingredient in the formulation.
  • Contraindicated in patients with a systemic fungal infection.
  • Contraindicated for use with live or live-attenuated vaccines while the patient is receiving immunosuppressive corticosteroid doses.
  • Contraindicated in patients with herpes simplex infection of the eye, except for short-term emergency use in acute sensitivity reactions.
  • Contraindicated in patients with vaccinia or varicella (chickenpox) infection, except for short-term emergency use in acute sensitivity reactions.

Drug interactions

Clinically relevant combinations

  • Anticholinesterase drugs used for myasthenia gravis may have reduced effect, and severe weakness may result, when combined with fludrocortisone.
  • Neuromuscular-blocking (anticholinergic) agents used in anesthesia may have enhanced or reduced effect when combined with fludrocortisone.
  • Oral anticoagulants such as warfarin may have their effect increased or decreased by fludrocortisone, requiring close monitoring.
  • Fludrocortisone may reduce the effectiveness of antidiabetic medications by raising blood sugar, requiring dose adjustment.
  • Fludrocortisone may reduce the effectiveness of antihypertensive medications.
  • Cyclosporine and fludrocortisone may each increase the other's activity when used together.
  • CYP3A4-inducing drugs, including carbamazepine, phenobarbital, phenytoin, and rifampin, can increase the clearance of fludrocortisone and reduce its effect.
  • CYP3A4-inhibiting drugs, including clarithromycin, ketoconazole, itraconazole, isoniazid, and ritonavir, can raise fludrocortisone blood levels and increase side-effect risk; this combination should generally be avoided.
  • Digoxin and other digitalis medicines combined with fludrocortisone increase the risk of irregular heart rhythm or digitalis toxicity due to low potassium.
  • Estrogens, including in oral contraceptives, can raise fludrocortisone blood levels.
  • NSAIDs, including acetylsalicylic acid (aspirin), combined with fludrocortisone increase the risk of stomach ulcers and gastrointestinal bleeding.
  • Potassium-depleting drugs, including amphotericin B and diuretics, combined with fludrocortisone increase the risk of low blood potassium.
  • Somatropin (growth hormone) effectiveness may be reduced by fludrocortisone.
  • Thyroid medications can change the clearance rate of fludrocortisone, requiring dose adjustment.
  • Vaccines may be less effective when given during fludrocortisone treatment.

Food interactions

Meal-related administration

  • Fludrocortisone can be taken with or without food.
  • Grapefruit and grapefruit juice must be avoided during treatment, since they can raise fludrocortisone blood levels and increase the risk of side effects.

Time of administration

Practical scheduling

  • Fludrocortisone is usually taken once daily at a consistent time each day, with or without food; avoid grapefruit and grapefruit juice around dosing.

Storage

Product handling

  • Store between 2°C and 8°C (refrigerated), protected from moisture.
  • Keep out of the reach and sight of children.

Patient take-away

Key counselling points for a quick closing summary

  • Fludrocortisone (JAMP Fludrocortisone) is a synthetic mineralocorticoid used to replace a hormone the adrenal glands are not making enough of.
  • Take it exactly as prescribed, at the same time each day, and never stop or change the dose without talking to your doctor.
  • Watch for and report signs of high blood pressure, swelling, unusual weight gain, or muscle weakness, which can signal too much medication.
  • Tell every healthcare provider that you take fludrocortisone before surgery, vaccination, or starting a new medicine.
  • Seek urgent medical attention for chest pain, severe shortness of breath, or signs of a severe allergic reaction.

References

Source material and product information

  1. Health Canada Product Monograph — Fludrocortisone 21-Acetate

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.